コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 bo (absolute between-group difference, -55.2 percentage points).
2 oints) to 25 percentage points (CI, 14 to 35 percentage points).
3 (-0.98 percentage points) and adults (-1.24 percentage points).
4 , except for influenza A by rapid NAATs (2.7 percentage points).
5 rimary end point (noninferiority margin, -10 percentage points).
6 erence, 8 percentage points; 95% CI, 2 to 13 percentage points).
7 r hospitals from -0.03+/-0.02 to 0.41+/-0.06 percentage points.
8 ed industry-sponsored studies by 6.2 to 34.0 percentage points.
9 dividual proteins with an average error of 7 percentage points.
10 he CI exceeds the noninferiority margin of 7 percentage points.
11 and white patients by 13 (95% CI, 0.11-0.16) percentage points.
12 r was tested at a noninferiority margin of 3 percentage points.
13 he prespecified noninferiority margin of 3.2 percentage points.
14 eatments was below the relevance margin of 3 percentage points.
15 ; the chosen margin of noninferiority was 10 percentage points.
16 but the absolute difference was only +/-0.2 percentage points.
17 (CI) of the differences in CRs not exceed 7 percentage points.
18 parison to exclude a difference of 5 or more percentage points.
19 Noninferiority margin was 10 percentage points.
20 d to show noninferiority with a margin of 15 percentage points.
21 .4 percentage points [95% CI, -41.7 to -27.0 percentage points]).
22 terol (5.7 percentage points [CI, 2.0 to 9.4 percentage points]).
23 9.4 percentage points [95% CI, -18.2 to -0.6 percentage points]).
24 16.5 percentage points [95% CI, 10.7 to 22.4 percentage points]).
25 -7.55 percentage points [CI, -12.85 to -2.25 percentage points]).
26 acaftor [600 mg/day]-ivacaftor group and 3.3 percentage points [0.2-6.4; p=0.036] in the lumacaftor [
27 per-measure decrease in prevalence was 0.94 percentage points (-1.76 to -0.13, p=0.023) and an avera
28 tor [600 mg per day]-ivacaftor group and 2.8 percentage points [1.7-3.8; p<0.0001] in the lumacaftor
29 ing increased correct case management by 7.9 percentage points (14.2%) but did not affect the use of
30 baseline ppFEV1 levels of 40 or higher (3.3 percentage points [2.3-4.4; p<0.0001] in the lumacaftor
31 marriage policies were associated with a 0.6-percentage point (95% CI, -1.2 to -0.01 percentage point
32 eased diabetes risk was estimated to be 0.85 percentage points (95% CI -0.030 to 1.728; p=0.058).
33 erage decrease in smoking prevalence of 1.57 percentage points (95% CI -2.51 to -0.63, p=0.001) and a
34 f indoor residual spraying increased by 6.63 percentage points (95% CI 0.79-12.47) after PMI implemen
35 f insecticide-treated nets increased by 8.34 percentage points (95% CI 0.86-15.83) and coverage of in
37 the total weekly number of hot flushes by 45 percentage points (95% CI 22-67) compared with the place
39 ; P=0.08); for lidocaine versus placebo, 2.6 percentage points (95% CI, -1.0 to 6.3; P=0.16); and for
40 opulation, with absolute differences of -7.4 percentage points (95% CI, -19 to 4.3 percentage points)
42 n the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage poi
44 ferences between CRs were estimated as -1.5% percentage points (95% CI, -9.6 to 6.5), thus the lower
45 mean HbA1c values in black persons being 0.4 percentage points (95% CI, 0.2 to 0.6 percentage points)
46 he market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage point
47 within 6 months after randomization was 18.5 percentage points (95% CI, 3.7 to 33.3; P=0.01); the una
49 emented, insurance coverage increased by 4.9 percentage points (95% CI, 4.4 to 5.4), not having to fo
51 tage points (95% CI: 37%-53%) higher with 24 percentage points (95% CI: -33% to -15%) fewer antibioti
52 same 274 physicians for the same case was 45 percentage points (95% CI: 37%-53%) higher with 24 perce
53 l rate for amiodarone versus placebo was 3.2 percentage points (95% confidence interval [CI], -0.4 to
54 the minocycline group, a difference of 27.6 percentage points (95% confidence interval [CI], 11.4 to
55 the likelihood of childhood asthma by 19.87 percentage points (95% confidence interval [CI], 3.37-36
56 ceiving the Housing Benefit increased by 1.8 percentage points (95% confidence interval: 1.0, 2.7) co
57 ty in India, with a difference of up to 55.1 percentage points (95% uncertainty interval 46.4-62.1) i
58 t-squares mean difference vs placebo was 3.7 percentage points [95% CI 0.5-6.9; p=0.024] in the lumac
59 04), but not improved operating margins (1.1 percentage points [95% CI, -0.1 to 2.3 percentage points
60 , -1.715 to 1.152]) or heart failure (-0.212 percentage points [95% CI, -0.532 to 0.108]), but it was
62 (difference-in-differences estimate, -0.282 percentage points [95% CI, -1.715 to 1.152]) or heart fa
63 (52.3% [520/995]) (adjusted difference, -9.4 percentage points [95% CI, -18.2 to -0.6 percentage poin
64 72.8% [287/394]) (adjusted difference, -34.4 percentage points [95% CI, -41.7 to -27.0 percentage poi
65 (risk difference [RD] for score >/=2, -2.05 percentage points [95% CI, -5.04 to 0.95 percentage poin
66 associated with improved excess margins (1.1 percentage points [95% CI, 0.1 to 2.0 percentage points]
67 (43.1% [236/547]) (adjusted difference, 16.5 percentage points [95% CI, 10.7 to 22.4 percentage point
68 he primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points])
70 experienced increased health insurance (7.4 percentage points [95% CI, 3.4 to 11.3 percentage points
71 lications (17.3% vs. 10.0%; difference, 7.29 percentage points [95% CI, 4.63 to 9.95 percentage point
73 63 [33.3%]) (absolute risk difference, 22.1 percentage points [95% CI, 5.5 to 38.7 percentage points
76 whites and African Americans (reduction of 1 percentage point; 95% CI, -0.02 to 0.04), but it was ass
78 ry cohort (adjusted differential change, 0.3 percentage point; 95% CI, 0.1-0.5 percentage points; or
79 ry cohort (adjusted differential change, 0.5 percentage point; 95% CI, 0.1-0.8 percentage points; or
80 3 cohorts (adjusted differential change, 0.5 percentage point; 95% CI, 0.1-0.9 percentage points; or
82 %) vs controls (38.6%) (a difference of 17.7 percentage points; 95% CI 4.2-31.2; P = .010), and clini
83 bservation (absolute difference in risk, 4.0 percentage points; 95% CI, -0.2 to 8.3; hazard ratio, 0.
87 new sites (3.1% vs. 10.3%; difference, -7.2 percentage points; 95% CI, -10.4 to -4.1), and infection
88 h low-risk disease (absolute difference, 0.7 percentage points; 95% CI, -10.5 to 11.8) or high-risk d
89 high-risk disease (absolute difference, 2.3 percentage points; 95% CI, -11.5 to 16.1) (P=0.08 for in
92 old members (1.7% vs. 4.1%; difference, -2.4 percentage points; 95% CI, -4.6 to -0.2) 7 to 14 days af
94 procedures (3.4% vs. 8.6%; difference, -5.2 percentage points; 95% CI, -8.2 to -2.2), skin infection
98 with observation (absolute difference, 26.2 percentage points; 95% CI, 19.0 to 32.9); treatment was
99 followed (80% v 74%; adjusted difference, 6 percentage points; 95% CI, 2 to 11 percentage points) an
100 h dyspnea (78% v 70%; adjusted difference, 8 percentage points; 95% CI, 2 to 13 percentage points).
102 iate-risk disease (absolute difference, 14.5 percentage points; 95% CI, 2.8 to 25.6) but not among th
104 erved (change from baseline at Week 24, +2.5 percentage points; 95% confidence interval [CI], -0.2 to
105 mmercial mesh (absolute risk difference, 0.7 percentage points; 95% confidence interval [CI], -1.2 to
106 bservation (absolute difference in risk, 5.5 percentage points; 95% confidence interval [CI], -1.5 to
107 he FFR group (difference in event rates, 0.7 percentage points; 95% confidence interval [CI], -1.5 to
108 storage group (absolute risk difference, 0.7 percentage points; 95% confidence interval [CI], -1.7 to
109 8% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to
110 shold group (absolute risk difference, -1.11 percentage points; 95% confidence interval [CI], -2.93 t
111 onazole group (absolute risk difference, 0.9 percentage points; 95% confidence interval [CI], -3.9 to
112 group in change in seizure frequency, -22.8 percentage points; 95% confidence interval [CI], -41.1 t
113 respectively; absolute risk difference, 0.1 percentage points; 95% confidence interval [CI], -5.7 to
114 medicine (80% v 73%; adjusted difference, 7 percentage points; 95% confidence interval [CI], 1 to 12
115 peutic class (difference in probability, 7.0 percentage points; 95% confidence interval [CI], 4.0 to
116 3%) in the CPAP group (risk difference, 12.3 percentage points; 95% confidence interval [CI], 5.8 to
117 a prescription-drug monitoring program (0.27 percentage points; 95% confidence interval, -0.05 to 0.5
118 lute difference in mortality with ZMapp, -15 percentage points; 95% confidence interval, -36 to 7).
119 absolute difference in readmission rate, 2.0 percentage points; 95% confidence interval, 0.4 to 3.5;
120 arathon dates (absolute risk difference, 3.3 percentage points; 95% confidence interval, 0.7 to 6.0;
121 (74.7% vs. 59.5%; absolute difference, 15.2 percentage points; 95% confidence interval, 6.1 to 24.2;
122 n the control group (adjusted difference, 33 percentage points; 95% credible interval, 24 to 44; post
123 al-flow pump group (absolute difference, 9.4 percentage points; 95% lower confidence boundary, -2.1 [
124 the Weibull model; absolute difference, 3.7 percentage points; 95% upper confidence limit, 12.56 per
125 35.6% of controls, for a difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31
126 irst 3 years after release from prison by 18 percentage points among nonwhites and 19 percentage poin
128 f tezacaftor-ivacaftor over placebo were 4.0 percentage points and 6.8%, respectively (P<0.001 for bo
129 and white patients by 9 (95% CI, 0.06-0.11) percentage points and between other minorities and white
130 erence, 6 percentage points; 95% CI, 2 to 11 percentage points) and "excellent" quality EOL care (57%
131 ixed-dose ICS-LABA agents in children (-0.98 percentage points) and adults (-1.24 percentage points).
132 oints; 95% confidence interval [CI], 1 to 12 percentage points) and help with dyspnea (78% v 70%; adj
133 d by 3.2 percentage points (CI, -6.0 to -0.4 percentage points), and total Medicare expenditures incr
134 r day (3.1 percentage points [CI, 2.1 to 4.0 percentage points] and 4.1 percentage points [CI, 2.7 to
135 rence, 5.1 percentage points [CI, 3.9 to 6.4 percentage points] and 4.6 percentage points [CI, 3.3 to
136 ence, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (trea
137 betes (5.2 percentage points [CI, 2.4 to 8.1 percentage points]) and high cholesterol (5.7 percentage
138 (7.4 percentage points [95% CI, 3.4 to 11.3 percentage points]) and Medicaid (10.5 percentage points
139 tates (3.6 percentage points [CI, 2.5 to 4.6 percentage points]), and from physicians who saw 25 to 4
140 stays (2.4 percentage points [CI, 0.7 to 4.2 percentage points]), and rates of diagnosis of diabetes
141 en [34%] vs. 39 of 238 [16%]; difference, 17 percentage points [based on unrounded data]; 95% confide
143 ighest level), and the outcome variable (the percentage point change in tobacco smoking prevalence be
144 .9 days), and in-home death decreased by 6.3 percentage points (CI, -11.2 to -1.5 percentage points)
145 lity of hospice enrollment decreased by 15.2 percentage points (CI, -19.6 to -10.9 percentage points)
146 robability of in-home death decreased by 3.2 percentage points (CI, -6.0 to -0.4 percentage points),
147 ility of hospice enrollment decreased by 6.7 percentage points (CI, -9.3 to -4.0 percentage points),
148 to forgo a physician visit increased by 2.4 percentage points (CI, 1.9 to 2.9), and having a checkup
149 (95% CI, -19 to 4.3 percentage points) to 25 percentage points (CI, 14 to 35 percentage points).
151 ke incidence (3.8% vs. 3.0%; difference, 0.8 percentage point [CI, -0.62 to 2.19 percentage points];
152 nts with low scores (RD for score >/=2, 0.20 percentage point [CI, -1.20 to 1.60 percentage points];
153 rtality rate (6.5% vs. 5.9%; difference, 0.6 percentage point [CI, -1.29 to 2.45 percentage points];
155 95 percentage points]; RD for score <2, 2.91 percentage points [CI, -0.43 to 6.25 percentage points];
156 urgitation (6.0% vs. 14.3%; difference, -8.3 percentage points [CI, -11.7 to -5.0 percentage points];
157 ceiving paclitaxel-eluting stents (RD, -7.55 percentage points [CI, -12.85 to -2.25 percentage points
158 7.89% to 10.92%) (absolute difference, -2.01 percentage points [CI, -4.18 to 0.16 percentage points];
159 or bleeding (10.5% vs. 7.7%; difference, 2.8 percentage points [CI, 0.57 to 5.04 percentage points];
160 tage points]), overnight hospital stays (2.4 percentage points [CI, 0.7 to 4.2 percentage points]), a
161 60 percentage points]; RD for score <2, 2.58 percentage points [CI, 0.71 to 4.46 percentage points];
162 isits to physicians in general practice (6.6 percentage points [CI, 1.3 to 12.0 percentage points]),
163 resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P <
164 ercentage points]) and high cholesterol (5.7 percentage points [CI, 2.0 to 9.4 percentage points]).
165 who saw fewer than 25 patients per day (3.1 percentage points [CI, 2.1 to 4.0 percentage points] and
166 s]), and rates of diagnosis of diabetes (5.2 percentage points [CI, 2.4 to 8.1 percentage points]) an
167 outside of Canada or the United States (3.6 percentage points [CI, 2.5 to 4.6 percentage points]), a
168 and better coverage than 1 year before (7.1 percentage points [CI, 2.7 to 11.5 percentage points]) c
169 s [CI, 2.1 to 4.0 percentage points] and 4.1 percentage points [CI, 2.7 to 5.5 percentage points], re
170 s [CI, 3.9 to 6.4 percentage points] and 4.6 percentage points [CI, 3.3 to 5.8 percentage points], re
171 arly-career physicians (rate difference, 5.1 percentage points [CI, 3.9 to 6.4 percentage points] and
172 11.3 percentage points]) and Medicaid (10.5 percentage points [CI, 6.5 to 14.5 percentage points]) c
173 ics increased TBI treatment completion by 31 percentage points compared with historical estimates.
174 fore (7.1 percentage points [CI, 2.7 to 11.5 percentage points]) compared with adults in nonexpansion
175 aid (10.5 percentage points [CI, 6.5 to 14.5 percentage points]) coverage and better coverage than 1
176 brupt 6.4 (95% confidence interval: 5.8-7.0) percentage-point decline in uninsured and a 9.6 (95% con
177 anagement quality (95% CI, -5.8 to 6.2); 0.7-percentage point decrease in maternity care quality (95%
178 ng the secondary outcomes, dPFV showed a 4.1 percentage point decrease in variability [95% confidence
179 95% confidence interval: 0.9, 7.0) and a 2.4-percentage-point decrease in the probability of being ab
180 in Medicaid (95% CI, 18.9-21.3) and an 18.2 percentage-point decrease in uninsured (95% CI, -19.3 to
181 .44; 95% CI, 1.23 to 1.68; P < .001), a 6.21 percentage point decreased probability of emergent admis
182 verall, non-white patients in MA had an 11.2 percentage-point decreased probability of severe PAD (P
183 ents (30%) in the control dressing group (18 percentage points difference, 95% CI 5-30; adjusted odds
184 itals for AMI (13.5% vs 13.7%, P = .02; -0.2 percentage-point difference) and HF (11.4% vs 11.9%, P =
185 ence) and HF (11.4% vs 11.9%, P = .008; -0.5 percentage-point difference), but higher for pneumonia (
189 istically significant in Massachusetts (+3.0 percentage-point difference, P = 0.385) whereas disparit
190 r all 3 conditions (AMI, 17.8% vs 17.2%, 0.6 percentage-point difference; HF, 24.7% vs 23.5%, 1.2 per
191 ge-point difference; HF, 24.7% vs 23.5%, 1.2 percentage-point difference; pneumonia, 19.4% vs 18.7%,
193 ties were higher in children by 12.1 to 31.8 percentage points, except for influenza A by rapid NAATs
194 tage points for tezacaftor-ivacaftor and 4.7 percentage points for ivacaftor alone (P<0.001 for both
195 es increased by 7-25 and 2-8 absolute median percentage points for PSC and WRA, respectively, compare
196 in the percentage of predicted FEV1 was 6.8 percentage points for tezacaftor-ivacaftor and 4.7 perce
197 he prevalence in adults of overweight by 1.0 percentage point (from 35.5% to 34.5%) and obesity by 2.
199 e concentration was in target range was 10.5 percentage points higher (95% CI 7.6-13.4; p<0.0001) dur
200 in both MA and control states had a 12 to 13 percentage-point higher probability of presenting with s
201 baseline child health problem predicted 2.5 percentage points' higher neighborhood poverty at take-u
202 ng 0.4 percentage points (95% CI, 0.2 to 0.6 percentage points) higher than those in white persons fo
203 d by 6.7 percentage points (CI, -9.3 to -4.0 percentage points), hospice duration decreased by 3.8 da
204 y 15.2 percentage points (CI, -19.6 to -10.9 percentage points), hospice duration decreased by 4.3 da
205 tive care quality (95% CI, -4.9 to 6.3); 0.2-percentage point improvement in chronic disease care man
206 re quality (95% CI, -6.4 to 5.0]); and a 0.6-percentage point improvement in patient experience ratin
207 nce before and after the exit of a plan: 0.7-percentage point improvement in preventive care quality
208 estimated that to reduce HIV incidence by 1 percentage point in a community, prevalence of viraemia
209 Furthermore, we observed a decrease of 10-20 percentage points in KO efficiency with 17nt sgRNAs comp
210 hropoiesis decreased by 4.4-14.6 and 0.3-9.5 percentage points in PSC and WRA, respectively, compared
211 alence of VAD decreased by a median of 11-18 percentage points in PSC compared with unadjusted values
212 ute risk of breast cancer mortality by a few percentage points in suitable women but can cause a seco
213 ificant absolute (+/-SE) excess of 5.4+/-1.9 percentage points in the rate of postoperative acute kid
214 egree in nursing was associated with a three percentage point increase in the fraction infants discha
215 feeding support was associated with an eight percentage point increase in the fraction of infants dis
216 x composite score was associated with a four percentage point increase in the fraction of infants dis
217 nin-based combination therapy coverage (3.56 percentage point increase, 95% CI -0.07-7.19), though th
218 reforms were associated with at least a 4.0-percentage-point increase in binge drinking (95% confide
219 pen enrollment, which corresponded to a 20.1 percentage-point increase in Medicaid (95% CI, 18.9-21.3
220 viremia (linear regression coefficient per 1-percentage-point increase in prevalence: 0.05 and 0.07,
221 nd a 9.6 (95% confidence interval: 6.5-12.6) percentage-point increase in rehabilitation at age 64 ve
223 CI, -11.88 to -0.54; P = .032), and an 8.13 percentage point increased probability of an elective ad
224 Yoga and PT participants were 21 and 22 percentage points less likely, respectively, than educat
225 facility (top 25%) was associated with a 2.3 percentage point lower newborn mortality (95% confidence
226 atment cessation, AR medication use was 18.8 percentage points lower (after adjustment for covariates
227 sis, the risk of primary nonadherence was 16 percentage points lower among patients given an electron
229 o, 1.27; 95% CI, 1.05-1.54; P = .02) and 4.0 percentage points lower predicted forced expiratory volu
230 ival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy.
233 es that passed MML than in other states (1.4-percentage point more; SE, 0.5; P = .004), as did cannab
234 ter than never-MML states in California (1.0-percentage point more; SE, 0.5; P = .06) and Colorado (1
235 ignificantly greater in late-MML states (1.6-percentage point more; SE, 0.6; P = .01), California (1.
237 int more; SE, 0.6; P = .01), California (1.8-percentage point more; SE, 0.9; P = .04), and Colorado (
239 riod, illicit use increased by the following percentage points: never-MML states, 3.5 (SE, 0.5); Cali
241 olyPhen-2, SIFT, and SNAP2) agreed within 10 percentage points on the percentage of rare SAVs predict
242 l rates across data sources were small (</=1 percentage point), OPTN only data often yielded slightly
244 hange, 0.3 percentage point; 95% CI, 0.1-0.5 percentage points; or 0.4% of the mean PDC [82.3%], P =
245 hange, 0.5 percentage point; 95% CI, 0.1-0.9 percentage points; or 0.6% of the mean PDC [78.2%], P =
246 hange, 0.5 percentage point; 95% CI, 0.1-0.8 percentage points; or 1.5% of the overall percentage usi
248 tice (6.6 percentage points [CI, 1.3 to 12.0 percentage points]), overnight hospital stays (2.4 perce
249 ction increased in allo-hMSC patients by 8.0 percentage points (p = 0.004) compared with 5.4 with aut
250 oup, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from
251 67 percentage points (95% CI, -2.18 to -1.18 percentage points; P < .001) and an increase in the mark
253 factors, the greatest difference found (1.8 percentage points; P = .088) was in mean deviation for s
254 es (difference-in-differences estimate, -8.2 percentage points; P<0.001) and rates of Medicaid covera
257 ls (difference-in-differences estimate, -7.9 percentage points; P=0.002) and an increase in reports o
258 re (difference-in-differences estimate, -3.4 percentage points; P=0.002) and in reports of worry abou
260 ge points; upper 97.5% confidence limit, 4.0 percentage points; P=0.02 for noninferiority; hazard rat
263 7.29 percentage points [95% CI, 4.63 to 9.95 percentage points]; P < 0.001) and major bleeding (10.5%
265 s (1.1 percentage points [95% CI, 0.1 to 2.0 percentage points]; P = .04), but not improved operating
268 nce, 2.8 percentage points [CI, 0.57 to 5.04 percentage points]; P = 0.012) but less frequent moderat
273 nce, 0.6 percentage point [CI, -1.29 to 2.45 percentage points]; P = 0.52) and stroke incidence (3.8%
274 al decline of -0.49 [95% CI, -0.81 to -0.16] percentage points per year relative to nontarget conditi
276 of work-related sick leave decreased by 0.28 percentage points (pp) from a pre-training mean of 1.56%
277 he prevalence of low TBI by a median of 4-14 percentage points (pps) in PSC and 1-3 pps in WRA compar
278 d prevalence of ID in PSC by a median of +25 percentage points (pps) when SF concentrations were used
279 ine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superio
280 =2, 0.20 percentage point [CI, -1.20 to 1.60 percentage points]; RD for score <2, 2.58 percentage poi
281 .05 percentage points [95% CI, -5.04 to 0.95 percentage points]; RD for score <2, 2.91 percentage poi
282 , increased latrine construction, and a 19.9 percentage point reduction in open defecation (p < 0.001
283 ESA boxed warning was associated with a 20.2-percentage-point reduction ( P < .001) in the likelihood
284 0.6-percentage point (95% CI, -1.2 to -0.01 percentage points) reduction in suicide attempts, repres
285 ma medication use fell by an additional 16.7 percentage points (relative to the pretreatment period)
286 second (FEV1) through week 24 (calculated in percentage points); relative change in the percentage of
287 mbined ART groups vs. 1.8%; difference, -1.3 percentage points; repeated confidence interval, -2.1 to
288 s] and 4.6 percentage points [CI, 3.3 to 5.8 percentage points], respectively), from physicians train
290 5, an average decrease in prevalence of 2.55 percentage points (SD 5.08; relative reduction 10.31%).
292 tates differed significantly for use (by 2.5 percentage points; SE, 0.9; P = .004) and disorder (1.1
293 ciated with teacher-facilitated CLTS was 8.2 percentage points smaller than for conventional CLTS (p
294 c demonstrated a mean deviation that was 2.5 percentage points smaller than subsequently published st
295 ed absolute reduction at 6 months of 9 to 10 percentage points; the reduction was primarily due to an
296 f -7.4 percentage points (95% CI, -19 to 4.3 percentage points) to 25 percentage points (CI, 14 to 35
297 patients in the CABG group (difference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 per
298 by 6.3 percentage points (CI, -11.2 to -1.5 percentage points) versus decedents with BMI of 20 kg/m2
299 p for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pr
300 ine training were >/=80%, and improved by 10 percentage points with refresher training, with no signi
301 and those who received chemotherapy was 1.5 percentage points, with the rate being lower without che
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。